[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Infanta Leonor University Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":108},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100640045","infectious-complications-in-hematological-patients-under-treatment-with-bispecific-antibodies-100640045",false,"NCT07609576","Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.","Multicenter Study Proposal: Infectious Complications in Hematological Patients Under Treatment With Bispecific Antibodies.","Inclusion Criteria:\n\n1. Adult patients (≥18 years) diagnosed with hematologic malignancies (e.g., multiple myeloma, non-Hodgkin lymphoma) who are receiving treatment with bispecific antibodies.\n2. Patients must have initiated BsAb therapy within 30 days prior to study enrollment.\n3. Ability to provide informed consent.\n4. Severe infections will be recorded the first year, but infectious events past confirmed relapse or new treatments for the underlying disease will not be recorded.","ALL","18 Years",{"count":19,"type":20},350,"ESTIMATED","2 Months","OBSERVATIONAL","This is a prospective, multicenter, observational cohort study involving patients with hematologic malignancies who are receiving bispecific antibody therapy. The primary objective of this study is to evaluate the incidence, type, and severity of infectious complications in hematologic patients undergoing treatment with bispecific antibodies.\n\nSecondary objectives include identifying risk factors associated with infection, comparing infectious outcomes across different hematologic malignancies and BsAb types, and assessing the impact of infections on overall treatment outcomes.",[25,26,27,28,29,30],"Lymphoma Neoplasms","Myeloma Multiple","Severe Infection","CMV Reactivation","Biespecific Treatment","Biespecific",[32,33],"prophylaxis","infections management","RECRUITING","2026-05-21",{"date":37,"type":38},"2026-05-27","ACTUAL",{"date":40,"type":38},"2026-05-14",{"date":42,"type":20},"2026-06-30",{"name":44,"class":45},"Infanta Leonor University Hospital","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":46},"100621557","observational-study-to-evaluate-the-effectiveness-of-doacs-for-secondary-thrombosis-prevention-in-low-risk-thrombotic-aps-patients-100621557","NCT07372170","Observational Study to Evaluate the Effectiveness of DOACS for Secondary Thrombosis Prevention in Low-risk Thrombotic APS Patients","Real-world Observational Study to Evaluate the Effectiveness and Safety of Direct Oral Anticoagulants Compared With Vitamin K Antagonists for Secondary Thrombosis Prevention in Low-risk Thrombotic Antiphospholipid Syndrome Patients","DOACS-APS","Inclusion Criteria:\n\n* Adults (≥18 years) with a diagnosis of thrombotic antiphospholipid syndrome.\n* Low-risk antiphospholipid syndrome defined by previous venous thrombosis and a single or double positive antiphospholipid antibody profile (lupus anticoagulant, anticardiolipin antibodies, and\u002For anti-beta-2-glycoprotein I antibodies).\n* Patients receiving long-term anticoagulant treatment with direct oral anticoagulants or vitamin K antagonists according to routine clinical practice.\n* At least 2 weeks of continuous anticoagulant treatment before study inclusion.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years.\n* Triple antiphospholipid antibody positivity.\n* History of arterial thrombosis.\n* Anticoagulation for indications other than secondary prevention of venous thrombosis related to antiphospholipid syndrome.",{"count":56,"type":20},600,"36 Months","This is an observational study designed to evaluate the effectiveness and safety of direct oral anticoagulants (DOACs) compared with vitamin K antagonists (VKAs) for the secondary prevention of thrombosis in patients with low-risk thrombotic antiphospholipid syndrome.\n\nAntiphospholipid syndrome is an autoimmune disorder associated with an increased risk of thrombotic events. Although VKAs have traditionally been the standard treatment, DOACs are increasingly used in clinical practice in selected patients, despite limited evidence in this setting.\n\nThis study includes patients with previous venous thrombosis and a low-risk serological profile who are treated with either DOACs or VKAs according to routine clinical practice. The primary objective is to compare thrombotic recurrence and bleeding events between both treatment strategies.\n\nThe results of this study will contribute to improving knowledge about the use of DOACs in patients with low-risk thrombotic antiphospholipid syndrome.",[60,61,62],"Antiphospholipid Syndrome (APS)","Venous Thrombosis (Disorder)","Thrombophilia",[64,65,66,67,68,69,70,71],"Direct oral anticoagulants","Vitamin K antagonists","Low-risk antiphospholipid syndrome","Secondary thrombosis prevention","Real-world study","Observational study","Venous Thrombosis","Antiphospholipid Antibody Profile","2026-01-28",{"date":74,"type":38},"2026-01-30",{"date":76,"type":38},"2025-12-01",{"date":78,"type":20},"2028-12-31",{"name":44,"class":45},{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":22,"phases":4,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":105,"leadSponsor":106,"locationsCount":107},"100616829","external-validation-of-the-clover-score-for-detecting-occult-cancer-in-venous-thromboembolism-patients-100616829","NCT07310693","External Validation of the CLOVER Score for Detecting Occult Cancer in Venous Thromboembolism Patients","External Validation of a Predictive Model for Occult Cancer Risk in Patients With Venous Thromboembolism Developed Using Machine Learning","CLOVER","Inclusion Criteria:\n\n* Age ≥18 years.\n* Objectively confirmed acute symptomatic venous thromboembolism (deep vein thrombosis and\u002For pulmonary embolism).\n* Ability to provide written or electronic informed consent.\n\nExclusion Criteria:\n\n* Suspicion of cancer during the initial diagnostic evaluation for VTE.\n* Participation in another interventional study that may interfere with outcomes.\n* Inability or refusal to provide informed consent.",{"count":89,"type":20},500,"2 Years","This study aims to externally validate the CLOVER score, a machine learning-based predictive model designed to identify patients with venous thromboembolism (VTE) who are at increased risk of having an occult cancer. The study includes a retrospective cohort of patients with acute symptomatic VTE diagnosed between 2000 and 2022, and a prospective cohort of consecutively recruited patients from December 2025 to December 2027. The CLOVER model will be applied to all participants, and its ability to discriminate between patients with and without occult cancer will be evaluated. The study also assesses clinicians' satisfaction with the web-based tool (CLOVER-Web) developed to facilitate the use of the score in clinical practice.",[93,94],"Venous Thromboembolism (VTE)","Occult Cancer",[94,96,97,98,99,100],"Venous thromboembolism","Machine learning","Prediction model","External validation","CLOVER score","2025-12-20",{"date":103,"type":38},"2025-12-30",{"date":76,"type":38},{"date":78,"type":20},{"name":44,"class":45},12,""]